Study Finds That Microdosing Psilocybin Mushrooms Improves Mood, Mental Health

July 15, 2022 10:31:50

New research has found evidence suggesting that magic mushrooms can improve the mood and mental health of an individual. The study analyzed about 1,100 subjects, with baseline evaluations being carried out at the start of the study then again between three or five weeks later.

For their research, investigators analyzed the results of psilocybin microdoses combined with vitamin-B3 (niacin) or lion’s mane mushrooms. The researchers’ objective was to identify any improvement in mental health and mood that was consistent across presence of mental health concerns, age and gender as well as improvements in psychomotor performance, which were specific to older individuals.

They discovered that while combining psilocybin with lion’s mane mushrooms or vitamin B3 didn’t affect the positive changes in mental health and mood, older individuals did experience improvements in their psychomotor performance through either lion’s mane mushrooms and psilocybin.

The study, which was coauthored by Paul Stamets, was funded by Quantified Citizen. Joseph M. Rootman of the Department of Psychology at the University of British Columbia also co authored the study. Its findings were reported in the “Scientific Reports” journal.

In a recent interview, Rootman stated that the research the group was conducting now would help generate discoveries associated with psychedelic microdosing for years to come.

It should be noted that this research used a variety of mushroom types, with Rootman explaining that they observed every patient’s recorded experience, which ranged between low, medium or high microdosed mushroom amounts. Low doses were 0.1g, medium doses were between 0.1 and 0.3g while high doses were more than 0.3g.

In their report, the researchers note that they also discovered that about 17% of their microdosing sample reported low dosages while roughly 72% reported medium dosages. Another 10% reported high dosages.

The authors of the studies added that while this was one of the first studies of its kind, more studies were needed to build a foundation showing how psilocybin could benefit humans.

In their conclusion, the researchers argued that further studies with larger samples and control groups that allowed for the examination of possible moderators such as gender, age and mental health status were needed to better appreciate the health consequences of this drug.

This comes after a second study discovered that psilocybin could be used to treat women suffering from major depressive disorder and HIV. Yet another study also found that psilocybin had the potential to treat depression while numerous other studies report that patients with terminal illnesses could use psilocybin to improve their quality of lives.

These research findings suggest that the R&D being undertaken on psychedelic compounds like psilocybin by various companies such as Silo Pharma Inc. (OTCQB: SILO) is likely to yield novel treatments that could shake up the mental health field for decades to come.

NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.